When we combined anti-PD-L1 with chemotherapy in our preclinical EMT6 model ± B7-H4, we observed no tumor response to paclitaxel chemotherapy alone and no improved tumor response with paclitaxel + anti-PD-L1 over anti-PD-L1 alone (Supplementary Fig. S6). Here, CD274 is linked to neoplasm.